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INTRODUCTION 
In their article, How Courts Adjudicate Patent Definiteness and 
Disclosure, John R. Allison and Lisa Larrimore Ouellette present a 
comprehensive study—thirty years’ worth of cases—of federal courts’ 
application of patent law’s written-description, definiteness, and 
enablement requirements.1 Using their own hand-coded dataset, 
Allison and Ouellette measure a number of interesting disparities in 
courts’ application of the two doctrines across various industries and 
technologies. But one of their results is simply shocking: the massive 
disparity in how courts apply patent law’s written-description 
requirement in pharmaceutical cases.2 In Allison and Ouellette’s 
study, pharmaceutical patents litigated as part of generic drug 
manufacturers’ Abbreviated New Drug Applications (ANDAs) 
before the U.S. Food and Drug Administration (FDA) fare no worse 
on courts’ written-description analyses than a control, 
industrial/business goods and services patents.3 But pharmaceutical 
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 1. John R. Allison & Lisa Larrimore Ouellette, How Courts Adjudicate Patent 
Definiteness and Disclosure, 65 DUKE L.J. 609 (2016); see also 35 U.S.C. § 112(a) (2012) 
(requiring that patents “contain a written description of the invention” and “enable any person 
skilled in the art to which it pertains . . . to make and use the same”).  
 2. See Allison & Ouellette, supra note 1, at 639 (defining pharmaceutical cases as “patents 
on drugs for treating diseases or other abnormal conditions in humans or animals, as well as 
processes for producing or using such drugs”). 
 3. See id. at 666 tbl.7. 
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patents litigated outside of the ANDA context fare substantially 
worse on courts’ written-description analyses—they are, by far, the 
worst performers on written description of any industry.4 Indeed, non-
ANDA pharmaceutical patents’ poor written-description score is the 
third most statistically significant result of any of the article’s sixty-
one comparisons across different definiteness and disclosure 
requirements, industries, jurisdiction, and procedural postures.5 
From the outset, there does not seem to be any ready 
explanation for this disparity. Pharmaceutical patents in both the 
ANDA and non-ANDA contexts are, obviously, part of the same 
technology class (pharmaceutical patents);6 they are typically owned 
by the same type of litigant, that is, brand pharmaceutical 
manufacturers;7 and they are typically litigated in the same 
jurisdictions.8 And yet, given the total sample size of pharmaceutical 
patents in Allison and Ouellette’s dataset—only sixty-five unique 
opinions9—it is unclear whether the differences that exist between 
courts’ written-description opinions of ANDA and non-ANDA 
patents can be teased apart by more robust statistical analysis. To that 
end, this brief response provides a qualitative analysis of Allison and 
Ouellette’s quantitative one. It briefly reviews ANDA versus non-
ANDA patent litigation in Part I. It engages in several hypotheses 
about differences between ANDA and non-ANDA pharmaceutical 
patent cases in Part II. Next, in Part III, it reviews the most significant 
ANDA and non-ANDA written-description cases from Allison and 
 
 4. See id. 
 5. See id. To be clear, statistical significance alone is no guarantee that a reported result is 
the result of nonrandom effects, and differences in p-value across multivariable comparisons 
may not amount to much. See generally STEPHEN T. ZILIAK & DEIRDRE N. MCCLOSKEY, THE 
CULT OF STATISTICAL SIGNIFICANCE (2008) (describing the myriad problems of overreliance 
on significance). Factors such as study design, small sample size, and the number of variables 
measured often produced statistically significant measurements that are, in fact, meaningless. 
See Regina Nuzzo, Scientific Method: Statistical Errors, NATURE (Feb. 12, 2014), http:// 
 www.nature.com/news/scientific-method-statistical-errors-1.14700 [https://perma.cc/BH D4-8P
FZ] (discussing problems with p values). Nonetheless, the huge disparity between ANDA and 
non-ANDA cases presented by Allison and Ouellette suggests something is worth investigating. 
 6. Allison & Ouellette, supra note 1, at 639–40. 
 7. See FED. TRADE COMM’N, GENERIC DRUG ENTRY PRIOR TO PATENT EXPIRATION: 
AN FTC STUDY 17–19 (2002), https://www.ftc.gov/sites/default/files/documents/reports/generic-
drug-entry-prior-patent-expiration-ftc-study/genericdrugstudy_0.pdf [https://perma.cc/WYV5-
C9VQ]. 
 8. BRIAN C. HOWARD & JASON MAPLES, LEX MACHINA: HATCH-WAXMAN / ANDA 
LITIGATION REPORT (2014) (on file with author). 
 9. See infra Appendix. 
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Ouellette’s dataset. In particular, it shows that different types of 
technologies at issue in some non-ANDA cases, such as biologics 
rather than small molecule drugs, play a role in courts’ written-
description assessments. Finally, Part IV provides several suggestions 
for areas of future research and litigation. 
I.  ANDA VERSUS NON-ANDA PATENT LITIGATION 
Before examining several hypotheses for Allison and Ouellette’s 
ANDA versus non-ANDA written-description disparity, it may be 
helpful to briefly recount how patent litigation differs procedurally in 
both contexts. As part of any New Drug Application with the FDA, a 
drug manufacturer must inform the agency which patents cover its 
drug.10 The FDA then dutifully lists the “corresponding patent 
numbers and expiration dates, in a fat, brightly hued volume called 
the Orange Book (less colorfully but more officially denominated 
Approved Drug Products with Therapeutic Equivalence 
Evaluations).”11 Drug companies wishing to manufacture a generic 
version of the original (brand) drug must then submit an Abbreviated 
New Drug Application, an ANDA, to the FDA certifying that its 
proposed generic product will not infringe the Orange Book-listed 
patents or that those patents are invalid. This certification is, by 
statute, an artificial act of patent infringement, and typically begins 
ANDA patent litigation.12 
By contrast, non-ANDA patent litigation can take several forms. 
Like ANDA patent litigation, it can be between a generic and brand 
drug manufacturer on patents not included in the Orange Book, both 
before and after the generic product has been approved by the FDA.13 
Non-ANDA patent litigation can also exist between two brand 
manufacturers with two separately approved drug products.14 And in 
 
 10. Jacob S. Sherkow, Administrating Patent Litigation, 90 WASH. L. REV. 205, 214–15 
(2015). 
 11. Caraco Pharm. Labs., Ltd. v. Novo Nordisk A/S, 132 S. Ct. 1670, 1676 (2012). 
 12. See Sherkow, supra note 10, at 214–15. 
 13. See, e.g., AbbVie Deutschland GmbH & Co., KG v. Janssen Biotech, Inc., 759 F.3d 
1285 (Fed. Cir. 2014) (demonstrating a non-ANDA patent-infringement action after approval); 
Eli Lilly & Co. v. Teva Pharm. USA, Inc., 619 F.3d 1329 (Fed. Cir. 2010) (demonstrating a non-
ANDA injunctive action prior to approval). 
 14. See, e.g., Complaint for Declaratory Relief (Patent Infringement), Medicis Pharm. 
Corp. v. Stiefel Labs., Inc., No. 5:10-CV-00621 (W.D. Tex. July 28, 2010). 
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rare circumstances, non-ANDA patent litigation can be fought 
between two rival generic manufacturers.15 
Despite these differences, ANDA and non-ANDA patent 
litigation is mostly alike. Both generally concern the same 
technological class of patents, that is, pharmaceutical patents. Both 
are almost always between business competitors of one sort or 
another—drug manufacturers seeking to sell similar, if not identical, 
products. Both employ the same procedures found in federal district 
court for all patent cases. And both groups of cases tend to be filed in 
the same districts.16 At a high level of abstraction, there is little reason 
that courts should apply differing written-description standards to 
these two groups of pharmaceutical cases—let alone ones that are 
subject to the dramatic differences reported by Allison and Ouellette. 
II.  HYPOTHESES ON THE ANDA VERSUS NON-ANDA WRITTEN-
DESCRIPTION DISPARITY 
In their article, Allison and Ouellette provide a few hypotheses 
for the ANDA versus non-ANDA written-description disparity. The 
first concerns differences in types of claims in ANDA versus non-
ANDA patents. Allison and Ouellette describe their reported 
discrepancy between the two types of cases on “written-description 
and definiteness grounds, likely because [non-ANDA] patents mostly 
relate to various methods rather than FDA-approved drug 
compositions.”17 The implication here is that claims on methods of 
using approved drugs are more likely to fall afoul of patent law’s 
definiteness requirement than claims on the drug compositions 
themselves. The belief that non-ANDA patent litigation tends to 
focus on “follow on patents,” rather than patents covering original 
drug compositions, is widespread.18 
 
 15. See, e.g., Teva Pharm. USA, Inc. v. Sandoz, Inc., 723 F.3d 1363 (Fed. Cir. 2013). 
 16. See generally HOWARD & MAPLES, supra note 8. 
 17. Allison & Ouellette, supra note 1, at 614. 
 18. See Janet Freilich, The Paradox of Legal Equivalents and Scientific Equivalence: 
Reconciling Patent Law’s Doctrine of Equivalents with the FDA’s Bioequivalence Requirement, 
66 SMU L. REV. 59, 61–62 (2013); see also Yaniv Heled, Patents vs. Statutory Exclusivities in 
Biological Pharmaceuticals—Do We Really Need Both?, 18 MICH. TELECOMM. & TECH. L. 
REV. 419, 468 n.218 (2012) (defining “follow on” or “secondary”  patents as “patents claiming 
(1) particular ways of formulating the product, (2) additional methods of manufacturing the 
[active pharmaceutical ingredient] or any of the intermediate compounds involved in making it 
and (3) additional methods of using the product or [active pharmaceutical ingredient] for 
treating additional medical conditions”). 
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Yet patents in both groups of Allison and Ouellette’s analysis—
ANDA and non-ANDA patents—contain both composition and 
method claims. Of the seven unique opinions that blocked written-
description challenges to ANDA patents, six concerned patents that 
covered method claims.19 And of these six cases, four concerned 
patents that claimed only methods of administration, rather than 
compositions.20 Empirically, at least, the ANDA–non-ANDA written-
description disparity cannot be explained by differences in the types 
of claims presented in the two types of cases. 
At a more theoretical level, Allison and Ouellette’s hypothesis 
puts to test a long-standing belief that patent claims covering drug 
compositions and methods of use differ in their judicial treatment. 
Even though claims covering drug compositions are for tangible 
things—and thus, perhaps, more easily described than abstract 
methods—composition claims can, and do, fail the written-description 
requirement. Claims for drug compositions often allow some 
variability in the drug’s chemical structure, usually in an effort to 
claim analogs to the principal drug. Drug composition claims may 
allow so much variability, however, as to make the written-
description requirement virtually impossible. In Boston Scientific 
Corp. v. Johnson & Johnson,21 for example, the U.S. Court of Appeals 
for the Federal Circuit famously upheld the invalidation of a patent 
claiming a rapamycin-eluting heart stent because the claims 
contemplated tens of thousands of rapamycin analogs, only a 
miniscule fraction of which were described.22 In other instances “a 
single generic [drug composition] claim can easily encompass 
millions, billions, or novemdecillions of compounds.”23 Aside from the 
strength or weakness of pharmaceutical composition patents, it is 
 
 19. Bone Care Int’l, LLC v. Pentech Pharm., Inc., 862 F. Supp. 2d 790 (N.D. Ill. 2012); 
Pfizer Inc. v. Teva Pharm. U.S.A. Inc., 882 F. Supp. 2d 643 (D. Del. 2012); Acorda Therapeutics 
Inc. v. Apotex Inc., No. 07-CV-4973, 2011 WL 4074116 (D.N.J. Sept. 6, 2011); Research Found. 
of State Univ. of N.Y. v. Mylan Pharm. Inc. (SUNY), 809 F. Supp. 2d 296 (D. Del. 2011); Alza 
Corp. v. Mylan Labs., Inc., 388 F. Supp. 2d 717 (N.D. W. Va. 2005); Astra Aktiebolag v. Andrx 
Pharm., Inc., 222 F. Supp. 2d 423 (S.D.N.Y. 2002). 
 20. Bone Care, 862 F. Supp. 2d at 793 (concerning U.S. Patent No. 5,602,116); Acorda 
Therapeutics Inc., 2011 WL 4074116 at *1 (concerning U.S. Patent No. 6,455,557); SUNY, 809 F. 
Supp. 2d at 298 (concerning U.S. Patent Nos. 7,211,267; 7,232,572); Astra, 222 F. Supp. 2d at 591 
(concerning U.S. Patent No. 5,093,342). 
 21. Boston Sci. Corp. v. Johnson & Johnson, 647 F.3d 1353 (Fed. Cir. 2011). 
 22. Id. at 1365. 
 23. Sean B. Seymore, Heightened Enablement in the Unpredictable Arts, 56 UCLA L. REV. 
127, 146 (2008) (footnotes omitted). 
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unclear that pharmaceutical method-of-use patents are, by their 
nature, relatively weaker than composition claims. Many 
pharmaceutical method-of-use claims, despite their perception as 
being weak, have easily vaulted over the written-description 
requirement.24 
Allison and Ouellette also suggest that ANDA patents may 
outperform their non-ANDA counterparts on various validity scores 
because they “are likely to have far more private economic value to 
their owners than many other kinds of patents, meaning that 
patentees will invest much more in fighting to preserve their 
validity.”25 It is indeed true that Orange Book-listed patents—or, at 
least, the market exclusivity that comes with them—are worth 
tremendous amounts of money.26 But here, too, the hypothesis does 
not seem to account for the relative performance of ANDA to non-
ANDA pharmaceutical patents. Non-ANDA patents protect a 
pharmaceutical product, too—one that, like an Orange Book-listed 
patent, quells competition in a lucrative arena. In Medicis 
Pharmaceutical Corp. v. Stiefel Laboratories, Inc.27—a non-ANDA 
patent dispute between two brand competitors28—Medicis’s patents 
protected a franchise worth roughly $400 million per year.29 It is 
unclear in situations like these whether the economic value of the 
patents, or the attorneys’ incentives to preserve those patents’ 
validity, shifts with such patents being listed (or not) in the Orange 
Book. It is also unclear why the written-description requirement, of 
all of patent law’s several substantive requirements, appears to 
greatly disfavor those patents not listed in the Orange Book. 
At PatCon V in 2015, at the University of Kansas, another patent 
scholar, David Schwartz, discussed yet another hypothesis for the 
ANDA–non-ANDA disparity described by Allison and Ouellette’s 
 
 24. See, e.g., Allergan Inc. v. Watson Labs. Inc., 869 F. Supp. 2d 456, 469 (D. Del. 2012) 
(concerning U.S. Patent No. 7,759,359, covering methods of treating bladder dysfunction by 
using trospium). 
 25. Allison & Ouellette, supra note 1, at 662. 
 26. C. Scott Hemphill, Paying for Delay: Pharmaceutical Patent Settlement as a Regulatory 
Design Problem, 81 N.Y.U. L. REV. 1553, 1568–69 (2005). 
 27. Complaint for Declaratory Relief (Patent Infringement), Medicis Pharm. Corp. v. 
Stiefel Labs., Inc., No. 5:10-CV-00621 (W.D. Tex. July 28, 2010) (N.B.: the author represented 
Medicis in this dispute). 
 28. Id. at 3–4. 
 29. Medicis Pharm. Corp., Annual Report, (Form 10-K) 71 (Dec. 31, 2012). The case was 
later dismissed by stipulation in 2013. Amended Stipulation and Order of Dismissal, Medicis 
Pharm. Corp. v. Stiefel Labs., Inc., No. 5:10-CV-00621 (W.D. Tex. June 26, 2013). 
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results. All things being equal, ANDA cases are more likely to settle 
than their non-ANDA counterparts because the stakes involved are 
often much higher. By and large, ANDA cases operate in the context 
of monopoly: at the time the infringement suit is filed, only the brand 
pharmaceutical product has been approved by the FDA.30 That 
monopoly is often worth billions of dollars to the patent holder. The 
uncertainty of litigation, therefore, frequently counsels brand 
manufacturers to settle with their generic rivals—often for large sums 
of money—to preserve their patents’ validity.31 Non-ANDA cases, 
however, often operate in the context of competition: at the time the 
infringement suit is filed, both rivals’ products have been approved by 
the FDA.32 To that end, the incentives for settling—and the 
importance of maintaining patent validity—are relatively low as 
compared to their ANDA counterparts. ANDA patent cases are 
therefore, according to Schwartz, likely to center on stronger 
patents—patents that brand drug manufacturers believe will survive 
generics’ challenges. 
Whether ANDA cases do settle more frequently than non-
ANDA cases remains to be seen. But, again, Schwartz’s hypothesis 
does not seem to explain why non-ANDA cases’ written-description 
scores fare more poorly than their enablement or indefiniteness 
scores. It seems odd to suggest, all things being equal, that ANDA 
holders’ incentives to maintain drug monopolies are only more 
sensitive to invalidity claims predicated on written-description, but 
not invalidity claims predicated on enablement or indefiniteness. 
Furthermore, if the stakes are high enough, a settlement-incentive 
theory that is uniquely sensitive to written-description-invalidity 
claims should work equally well in the non-ANDA context. 
Preventing competitors from entering a $400-million marketplace, as 
in Medicis, should provide an equal incentive to patent holders in the 
ANDA and non-ANDA contexts. 
None of the strongest hypotheses seem to provide satisfying 
answers to the chasm in written-description treatment between 
ANDA and non-ANDA cases. And yet, Allison and Ouellette’s 
evidence clearly demonstrates the existence of such a disparity. The 
answers, if clear ones exist, likely lie in the cases themselves. 
 
 30. See 21 U.S.C. § 355(j) (2010). 
 31. Hemphill, supra note 26, at 1557. 
 32. See supra notes 13–15 and accompanying text. 
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III.  ANDA VERSUS NON-ANDA WRITTEN-DESCRIPTION 
DECISIONS 
Allison and Ouellette’s dataset concerning § 112 decisions in 
pharmaceutical patent cases consists of sixty-five unique opinions: 
thirty-six ANDA opinions and twenty-nine non-ANDA opinions. Of 
the ANDA opinions, ten had a written-description score of at least 
one on either Allison and Ouellette’s five-level scale or three-level 
scale.33 Of the non-ANDA opinions, nine had a written-description 
score of at least one. Thus, it would appear that the written-
description requirement was at issue in roughly equal proportions: 
27.7 percent (10/36) of ANDA cases and 31.0 percent (9/29) of non-
ANDA cases.34 
Interestingly, Allison and Ouellette’s written-description 
disparity arises in how the courts dispose of these issues. Of the ten 
ANDA opinions where written-description was at issue, seven 
declared valid all of the claims of the asserted patents under the 
written-description requirement; one declared at least some of the 
claims invalid for lacking a proper written description; and two 
concluded that factual issues prevented a resolution of the 
defendants’ written-description arguments. But of the nine non-
ANDA cases discussing the written-description requirement, five 
declared at least one claim of the asserted patent invalid for failing 
the written-description requirement; three concluded that factual 
issues prevented a disposition of the defendants’ written-description 
arguments; and only one affirmatively rebuffed the defendant’s 
written-description challenges.35 
To put these numbers in this context, Allison and Ouellette’s 
dataset shows that out of thirty-six ANDA opinions, only a single 
one—Alcon Research Ltd. v. Barr Laboratories Inc.36—invalidated a 
 
 33. Allison and Ouellette describe their two scales as follows. First, the five-level scale  
record[s] the relative strength of each decision on the following . . . (1) invalid as a 
matter of law; (2) fact issue followed by a ruling of invalidity; (3) fact issue remaining; 
(4) fact issue followed by a ruling of validity; or (5) valid as a matter of law. . . . We 
also created a coarser one-to-three scale by collapsing “as a matter of law” and “fact 
issue followed by a validity or invalidity ruling” to produce “total valid” and “total 
invalid” outcomes on each of the three issues. 
Allison & Ouellette, supra note 1, at 631.  
 34. See infra Appendix. 
 35. See id. 
 36. Alcon Research Ltd. v. Barr Labs. Inc., 837 F. Supp. 2d 364 (D. Del. 2011), aff’d in part, 
rev’d in part, 745 F.3d 1180 (Fed. Cir. 2014). 
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patent’s claims on lack-of-written-description grounds.37 By contrast, 
out of twenty-nine non-ANDA opinions, only a single one—Allergan, 
Inc. v. Watson Laboratories, Inc.38—rejected the defendants’ written-
description arguments,39 while five others invalidated the claims at 
issue for lacking a proper written description. In short, the disparity 
uncovered by Allison and Ouellette seems to show that, while both 
ANDA and non-ANDA litigants raise written-description issues in 
relatively equal proportions, courts in the ANDA context rarely, if 
ever, invalidate those patents on written-description grounds. 
This comparative examination shows one surprising facet: courts’ 
differing levels of engagement with the merits of the written-
description arguments. The single opinion to invalidate an ANDA 
patent on written-description grounds, Alcon, appears to have done 
so reluctantly and with little analysis. Alcon’s patents covered 
Travatan, a medication indicated for treating glaucoma and ocular 
hypertension that used castor oil to stabilize the formulation’s 
components.40 Alcon’s patent’s claims, however, did not specify the 
precise quantities of castor oil for either effective preparation or 
treatment.41 To that end, the district court concluded that the patents 
were too broad to be enabling.42 But the court’s opinion came on the 
heels of Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co.,43 a seminal 
case from the U.S. Court of Appeals for the Federal Circuit that 
separated enablement and written-description as free-standing 
doctrines.44 Perhaps confused by the application of these two 
doctrines—or cuing up the case for a single appeal—the Alcon court 
concluded that the breadth of the patent’s claims merited invalidation 
under both theories: 
[W]e believe that the Section 112, first paragraph, analysis in this 
case proceeds more cleanly through the enablement framework than 
through a written description-type inquiry. Nonetheless, given the 
current state of written description jurisprudence, we find that the 
castor oil patent claims also fail the written description requirement 
 
 37. Id. at 392. 
 38. Allergan, Inc. v. Watson Labs., Inc., 869 F. Supp. 2d 456 (D. Del. 2012). 
 39. Id. at 469. And even there, the court ultimately invalidated the asserted patents for 
obviousness. Id. at 519. 
 40. Alcon Research Ltd., 837 F. Supp. 2d at 367. 
 41. Id. at 381. 
 42. Id. 
 43. Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010). 
 44. Id. at 1351. 
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for essentially the same reasons that they fail the enablement 
requirement: the art in question is highly unpredictable and the 
claims are extremely broad, but the written description is relatively 
limited.45 
By contrast, the only non-ANDA opinion to uphold the asserted 
patents on written-description grounds—Allergan—did so after a 
lengthy analysis of the written-description requirement and expert 
testimony as to the substance of the claims.46 In contrast to the claims 
at issue in Alcon, the claim discussed in Allergan was narrow: it 
required that the maximum concentration of the drug, trospium, in 
patients’ blood fell below a much larger range than disclosed in the 
patent’s specification.47 The court examined testimony from three 
experts on this aspect of the invention alone, comparing their 
testimony to four formulations of the same invention disclosed in the 
patent.48 Ultimately, after finding one expert’s testimony to be the 
most persuasive, the court concluded that the patent “provided 
guidance to those skilled in the art that the low [maximum blood 
concentration] range limitation is an aspect of the invention and the 
applicants were in possession of it.”49 
Apart from the level of engagement, the non-ANDA and 
ANDA opinions in Allison and Ouellette’s dataset appear to concern 
differing technologies. For example, by statutory design, the ANDA 
opinions exclusively cover “small molecule” drugs, which are 
relatively simple to describe in writing. Biologics—the focus of 
several non-ANDA cases in Allison and Ouellette’s dataset—
however, are larger, complex molecules that are much more difficult 
to describe in writing. Indeed, in many instances, patentees of 
biologics can only describe them in functional terms: what they bind 
to or from where they are derived, rather than their precise chemical 
structure.50 For that reason, at the margins at least, non-ANDA 
patents may be more susceptible to written-description attacks than 
their ANDA counterparts. 
 
 45. Alcon Research Ltd., 837 F. Supp. 2d at 384 (footnote omitted). 
 46. Allergan, Inc. v. Watson Labs., Inc., 869 F. Supp. 2d 456, 497–99 (D. Del. 2012). 
 47. Id. at 498–99. 
 48. Id. 
 49. Id. at 499. 
 50. See generally Jason Kanter & Robin Feldman, Understanding and Incentivizing 
Biosimilars, 64 HASTINGS L.J. 57 (2012) (discussing the differences in patents claiming biologics 
relative to small molecule therapies). 
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Indeed, of the five non-ANDA opinions finding the asserted 
patents invalid for lacking a sufficient written description, three 
appear to have concerned non-traditional pharmaceutical 
technologies. Both AbbVie Deutschland GmbH & Co. v. Janssen 
Biotech, Inc.51 and Centocor Ortho Biotech, Inc. v. Abbott 
Laboratories,52 for example, concerned antibodies—large, complex 
biologics famously difficult to describe.53 And in both cases, the 
Federal Circuit faulted the patentee for claiming, but failing to fully 
describe, a broad “genus” of antibodies. In AbbVie, the Federal 
Circuit affirmed a jury’s finding that the asserted patents did not 
“adequately describe representative antibodies to reflect the 
structural diversity of the claimed genus,” a problem that is prevalent 
“in technology fields that are highly unpredictable, where it is difficult 
to establish a correlation between structure and function for the 
whole genus or to predict what would be covered by the functionally 
claimed genus.”54 In Centocor, the Federal Circuit was incredulous 
that “the patent broadly claim[ed] a class of antibodies that 
contain[ed] human variable regions, [even though] the specification 
d[id] not describe a single antibody that satisfie[d] the claim 
limitations.”55 Similarly, in University of Rochester v. G.D. Searle & 
Co.,56 the court was tasked with determining the sufficiency of the 
patent’s description of methods of genetically inhibiting PGHS-2, a 
protein involved in inflammation.57 Because the patent described the 
invention in functional rather than tangible terms, the Federal Circuit 
upheld the invalidation of the patent, noting that “[e]ven with the 
three-dimensional structures of [related] enzymes . . . in hand, it may 
even now not be within the ordinary skill in the art to predict what 
compounds might bind to and inhibit them . . . .”58 
Competing problems of broad claiming and technological 
uncertainty are simply unlikely to occur in small-molecule ANDA 
 
 51. AbbVie Deutschland GmbH & Co. v. Janssen Biotech, Inc., 759 F.3d 1285 (Fed. Cir. 
2014). 
 52. Centocor Ortho Biotech, Inc. v. Abbott Labs., 636 F.3d 1341 (Fed. Cir. 2011). 
 53. Douglas G. Metcalf, Therapeutic Antibody Patent Infringement Litigation: Untested and 
Uncertain Litigation Strategies Underpin Patents Protecting Multibillion-Dollar Pharmaceuticals, 
19 B.U. J. SCI. & TECH. L. 194, 203–04 (2013). 
 54. AbbVie Deutschland GmbH & Co., 759 F.3d at 1301. 
 55. Centocor, 636 F.3d at 1350–51. 
 56. Univ. of Rochester v. G.D. Searle & Co., 358 F.3d 916 (Fed. Cir. 2004). 
 57. Id. at 917–18. 
 58. Id. at 925. 
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cases—something borne out by the seven ANDA opinions finding the 
asserted claims valid despite written-description objections. In those 
cases, the courts confronted traditional pharmaceutical claims 
directed toward a chemically precise compound, formulations, or 
methods of using a previously known drug. The patent at issue in 
GlaxoSmithKline LLC v. Banner Pharmacaps, Inc.,59 for example, 
concerned composition claims—that is, claims covering a specific 
chemical compound dutasteride.60 There, the court simply concluded 
that “under each side’s construction and reading of the specification, 
the description matches the claim, and regardless of which side is 
right, the description remains entirely based on structure of the 
compound and its process of creation. . . . We have no precedent . . . 
[that this] would be insufficient.”61 Similarly, in Acorda Therapeutics 
Inc. v. Apotex Inc.,62 the asserted claims covered a method of treating 
a spastic patient with tizanidine, a well-known drug, as well as a way 
of manufacturing the treatment.63 The court’s written-description 
analysis in Acorda consisted of a single, short paragraph finding “no 
lack of description in the specification for the claim scope,” especially 
because “the claim term’s inclusion of [the contested term] came 
directly from its express definition in the specification.”64 And in 
Pfizer Inc. v. Teva Pharmaceuticals U.S.A. Inc.,65 the district court 
sided with the patent holder’s expert to find that the patent’s 
description of the drug and its variants proved that “chemists would 
understand what the disclosure meant” and would be “more than 
sufficient to convey to those of skill in the art the subject matter of 
the claimed invention and that the inventors were in ‘possession of 
it.’”66 
From a broader perspective, the substance of these decisions 
suggests that technology class plays a crucial role in courts’ written-
description determinations of pharmaceutical patents. The more basic 
the pharmaceutical technology—simple compounds, traditional 
formulations, or typical methods of use—the less likely it is that 
 
 59. GlaxoSmithKline LLC v. Banner Pharmacaps, Inc., 744 F.3d 725 (2014). 
 60. Id. at 726–27.  
 61. Id. at 730. 
 62. Acorda Therapeutics Inc. v. Apotex Inc., No. 07-CV-4973, 2011 WL 4074116 (D.N.J. 
Sept. 6, 2011). 
 63. Id. at *2.  
 64. Id. at *25. 
 65. Pfizer Inc. v. Teva Pharm. U.S.A. Inc., 882 F. Supp. 2d 643 (D. Del 2012). 
 66. Id. at 702.  
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challengers will be able to prove, by clear and convincing evidence, 
that the asserted patents lack a sufficient written description. But the 
more complex the technology—derivative compounds with numerous 
radical groups, new formulations or dosage forms, or atypical 
methods of use—the more likely it is that challengers will be able to 
prove a lack of written description. Put another way, the more 
complex or unpredictable the technology, the easier it will be to prove 
that the claims are not sufficiently described. As a consequence, 
ANDA patents will seem to survive written-description challenges 
more frequently than their non-ANDA cousins because ANDA 
patents—by their nature—focus only on traditional, small-molecule 
pharmaceuticals. Furthermore, where this analysis fails, it seems to 
fail only at the extremes. Where courts have given either short shrift 
or Talmudic thoroughness to their written-description analyses, 
results, like those in Alcon and Allergan, seem more likely to occur. 
In all, a more detailed examination of the cases scoring at least Level 
One on Allison and Ouellette’s written-description scales suggests 
that the ANDA/non-ANDA disparity is perhaps best explained not 
by “litigation metrics”—the value in dispute or the likelihood of 
settlement, for example—but by the underlying technology itself. 
VI.  FUTURE RESEARCH 
Allison and Ouellette note that their “results on how § 112 has 
been applied in practice will be helpful in evaluating current 
proposals for reform, and our rich dataset—which we are making 
publicly available—will enable more systematic [future] studies of 
these critical doctrines.”67 This is undoubtedly true for their written-
description results in the pharmaceutical context. To that end, Allison 
and Ouellette’s study—and the analysis here—suggests several 
avenues for further research, both quantitative and, perhaps more 
importantly, qualitative. 
First, Allison and Ouellette’s dataset runs through 2012. As a 
result, the dataset does not include two major patent decisions that 
may significantly affect how courts apply the written-description 
doctrine to pharmaceutical technologies going forward. The first of 
these is the Federal Circuit’s en banc decision of the Ariad case, 
discussed earlier.68 Although that case was decided in 2011, and is 
 
 67. Allison & Ouellette, supra note 1, at 612. 
 68. See supra note 44 and accompanying text. 
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captured in Allison and Ouellette’s dataset, the implications of Ariad 
are likely to be recognized in the future—to the detriment of 
patentees in both the ANDA and non-ANDA contexts. Ariad’s 
conclusion, that the written-description doctrine exists separately 
from either definiteness or enablement, may become additional 
fodder for patent challengers. The second case is the Supreme Court’s 
recent decision in FTC v. Actavis, Inc.69 That decision barred many 
types of settlements between brand pharmaceuticals and generic 
challengers in ANDA cases.70 With these “reverse payment” 
settlements now off the table, it appears that more ANDA cases will 
be litigated to judgment—thus, potentially producing more 
invalidating-written-description opinions than exist currently. 
Because these shifts in doctrine portend a greater number of ANDA 
patents failing under the written-description requirement, a post-
Ariad and Actavis follow-up study to Allison and Ouellette’s article 
would be informative. 
A second avenue for further research concerns the rise of 
biologic drugs or, simply, “biologics.” An increasing number of top-
selling therapeutics are biologics.71 Current law mandates that 
biologics patents are litigated outside of the ANDA context.72 But 
with the 2009 Biologics Price Competition and Innovation Act 
(BPCIA)—and with a recent decision by the Federal Circuit 
clarifying the BPCIA—there may be an increasing amount of 
ANDA-style patent-litigation.73 The BPCIA, nonetheless, has thus far 
proven famously fruitless, with only a single generic biologic—termed 
a biosimilar—approved to date.74 Should the FDA approve an 
increasing number of biosimilars—an act likely to generate an 
increasing amount of non-ANDA patent litigation—commentators 
interested in the written-description requirement may want to revisit 
Allison and Ouellette’s study with fresh data. 
Lastly, a more thorough analysis of Allison and Ouellette’s 
dataset would also review pharmaceutical cases where the written-
 
 69. FTC v. Actavis, Inc., 133 S. Ct. 2223 (2013). 
 70. Id. at 2237–38. 
 71. Jeanne Yang, Note, A Pathway to Follow-On Biologics, 3 HASTINGS SCI. & TECH. L.J. 
217, 217 (2011). 
 72. See Kanter & Feldman, supra note 50, at 59. 
 73. See, e.g., Amgen Inc. v. Sandoz Inc., 794 F.3d 1347 (Fed. Cir. 2015). 
 74. See Lindsay Kelly, Biologics in the Practice of Law, 39 HARV. J.L. & PUB. POL’Y 21, 23 
(2016) (“[O]nly a few biosimilar applications have been filed with the Food and Drug 
Administration (FDA), and just one biosimilar has been approved to date.”). 
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description requirement was not litigated. A review of the related 
patents and their specifications may prove informative as to why 
parties did not litigate such issues to judgment. Such an investigation 
may uncover some of the technology-specific effects addressed here—
that, for example, traditional technologies in both the ANDA and 
non-ANDA contexts did not give rise to written-description issues. 
Here, as in other instances, the “curious incident” worthy of study lies 
in the dog that did not bark.75 
More generally, Allison and Ouellette’s study provides insight 
into the future of empirical versus doctrinal patent scholarship. The 
authors’ methodology appears to be helpful for collecting and 
analyzing, at a high level, a large number of otherwise complex and 
doctrinally diverse cases. Simply determining—and counting—what 
constitutes a “written-description opinion,” and what to do where 
multiple patents are at issue, is difficult. This is especially the case 
when done in bulk. But, more than anything, Allison and Ouellette’s 
study demonstrates that it is possible to define a closed universe of 
cases for a given doctrine or technology area, and to weigh their 
outcomes and the levels of their analyses. 
Their study also demonstrates, however, the limits of larger 
empirical assessments for narrower doctrines or technology classes. In 
some data slices—such as non-ANDA pharmaceutical cases that 
upheld the validity of a patent subject to written-description 
challenges—we have an N of 1.76 This means that the power of their 
specific results for any given case is open to further qualitative 
analysis—and possible contradiction. As demonstrated by the Alcon 
decision, some questions will simply turn on idiosyncrasies that 
empirical analyses cannot capture. Allison and Ouellette’s article, 
therefore, shows the importance of close doctrinal analyses of cases.77 
Their study, and others like it, provide excellent jumping-off points 
for further research—both quantitative and quantitative. 
 
 75. Cf. Dan L. Burk, The Curious Incident of the Supreme Court in Myriad Genetics, 90 
NOTRE DAME L. REV. 505, 505–06 (2014) (comparing the Supreme Court’s silence on Mayo 
Collaborative Services v. Prometheus Laboratories, Inc. in the later-decided Association for 
Molecular Pathology v. Myriad Genetics, Inc. to be like the “curious incident” of the dog that 
did not bark in the Sherlock Holmes tale, Silver Blaze). 
 76. See, e.g., Allergan, Inc. v. Watson Labs., Inc., 869 F. Supp. 2d 456, 459 (D. Del. 2012) 
(invalidating a patent, but not for written-description issues). 
 77. See supra notes 40–65 and accompanying text. 
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CONCLUSION 
Allison and Ouellette’s article concerning patent law’s written-
description requirement provides a shocking disparity between 
pharmaceutical cases in the ANDA versus non-ANDA contexts. 
Scholars, including Allison and Ouellette, have provided several high-
level hypotheses as to these results, but none appear to provide 
satisfactory answers. A further examination of the underlying cases in 
Allison and Ouellette’s dataset provides two insights: One, the 
written-description requirement is at issue in roughly equal numbers 
in ANDA versus non-ANDA cases. But, two, for the decisions that 
do discuss the written-description requirement, almost every ANDA 
case survives the courts’ written-description analyses, while a large 
number of non-ANDA cases fail them. A closer examination of these 
cases reveals that this disparity is likely due to particular 
idiosyncrasies in each case, rather than a high-level of assessment of 
whether they arose in the ANDA or non-ANDA contexts. Allison 
and Ouellette’s article, in turn, demonstrates the power and limits of 
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APPENDIX 
UNIQUE PHARMACEUTICAL PATENT OPINIONS IN ALLISON & 
OUELLETTE (2016) 
Legend:  1 = Written Description Valid as a Matter of Law; 2 = Written Description Fact Issue—
Valid; 3 = Written Description Invalid as a Matter of Law; 4 = Written Description Fact Issue—
Invalid; 5 = Written Description Fact Issue—Remaining  
 
ANDA Opinions 1 2 3 4  5 
Written Description 
3-level 5-level 
Acorda Therapeutics Inc. v. Apotex Inc., No. 
07-CV-4973, 2011 WL 4074116 (D.N.J. Sept. 
6, 2011)   1       3 4 
Alza Corp. v. Mylan Labs., Inc., 388 F. Supp. 
2d 717 (N.D. W. Va. 2005)  1    3 4 
Astra Aktiebolag v. Andrx Pharm., Inc., 222 
F. Supp. 2d 423 (S.D.N.Y. 2002)   1       3 4 
Bone Care Int’l, LLC v. Pentech Pharm., Inc., 
862 F. Supp. 2d 790 (N.D. Ill. 2012)   1       3 4 
GlaxoSmithKline LLC v. Banner 
Pharmacaps, Inc., 744 F.3d 725 (Fed. Cir. 
2014)   1       3 4 
Pfizer Inc. v. Teva Pharm. U.S.A. Inc., 882 F. 
Supp. 2d 643 (D. Del. 2012)   1       3 4 
Research Found. of State Univ. of N.Y. v. 
Mylan Pharm. Inc., 809 F. Supp. 2d 296 (D. 
Del. 2011)   1       3 4 
Abbott Labs. v. Andrx Pharm., Inc., 473 F.3d 
1196 (Fed. Cir. 2007)         1 2 3 
Glaxo Wellcome Inc. v. Eon Labs Mfg. Inc., 
No. 00-CV-9089, 2003 WL 22004874 
(S.D.N.Y. Aug. 22, 2003)         1 2 3 
Alcon Research Ltd v. Barr Labs., 837 F. 
Supp. 2d 364 (D. Del. 2011)       1   1 2 
Abbott Labs. v. TorPharm Inc., 300 F.3d 1367 
(Fed. Cir. 2002)      0 0 
Alza Corp. v. Mylan Labs., Inc., 349 F. Supp. 
2d 1002 (N.D. W. Va. 2004)           0 0 
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Legend:  1 = Written Description Valid as a Matter of Law; 2 = Written Description Fact Issue—
Valid; 3 = Written Description Invalid as a Matter of Law; 4 = Written Description Fact Issue—
Invalid; 5 = Written Description Fact Issue—Remaining  
 
ANDA Opinions 1 2 3 4  5 
Written Description 
3-level 5-level 
Aventis Pharma Deutschland GmbH v. Lupin 
Ltd., No. 2:05-CV-421, 2006 WL 2008962 
(S.D.N.Y. July 17, 2006)           0 0 
Bristol-Myers Squibb Co. v. Andrx Pharm., 
Inc., 343 F. Supp. 2d 1124 (S.D. Fla. 2004)           0 0 
Cephalon, Inc. v. Watson Pharm., Inc., 707 
F.3d 1330 (Fed. Cir. 2013)      0 0 
Eli Lilly & Co. v. Actavis Elizabeth LLC, 435 
F. App’x 917 (Fed. Cir. 2011)           0 0 
Eli Lilly & Co. v. Sicor Pharm. Inc., 705 F. 
Supp. 2d 971 (S.D. Ind. 2010)           0 0 
Eli Lilly & Co. v. Teva Parenteral Medicines, 
No. 1:10-CV-1376, 2012 WL 2358102 (S.D. 
Ind. June 20, 2012)           0 0 
Glaxo Grp. Ltd v. Teva Pharm. USA Inc., No. 
02-CV-219, 2004 WL 1875017 (D. Del. Aug. 
20, 2004)      0 0 
Glaxo Grp. Ltd. V. Apotex Inc., 376 F.3d 1339 
(Fed. Cir. 2004)           0 0 
Glaxo Wellcome Inc. v. EON Labs Mfg. Inc., 
No. 00-CV-9089, 2002 WL 1874830 (S.D.N.Y. 
Aug. 13, 2002)      0 0 
Glaxo Wellcome Inc. v. Eon Labs Mfg. Inc., 
No. 00-CV-9089, 2003 WL 22004871 
(S.D.N.Y. Aug. 22, 2003)           0 0 
Imperial Chemical Indus. PLC v. Barr Labs., 
795 F. Supp. 619 (S.D.N.Y. 1992)      0 0 
Imperial Chemical Indus. PLC v. Danbury 
Pharmacal Inc., 777 F. Supp. 330 (D. Del. 
1991)           0 0 
Medicis Pharmaceutical Corp. v. Actavis Mid 
Atl. LLC, No. 11-409-LPS-CJB, 2012 WL 
2126873 (D. Del. June 12, 2012)           0 0 
  
SHERKOW IN PRINTER FINAL (DO NOT DELETE) 3/23/2016  10:34 PM 
2016] DESCRIBING DRUGS 145 
Legend:  1 = Written Description Valid as a Matter of Law; 2 = Written Description Fact Issue—
Valid; 3 = Written Description Invalid as a Matter of Law; 4 = Written Description Fact Issue—
Invalid; 5 = Written Description Fact Issue—Remaining  
 
ANDA Opinions 1 2 3 4  5 
Written Description 
3-level 5-level 
Momenta Pharm., Inc. v. Amphastar Pharm., 
Inc., 887 F. Supp. 2d 303 (D. Mass. 2012)      0 0 
Ortho-McNeil Pharm. Inc. v. Kali Labs., 482 
F. Supp. 2d 478 (D.N.J. 2007)           0 0 
Ortho-McNeil Pharm. Inc. v. Mylan Labs., 
Inc., No. 04-CV-1689, 2006 WL 2865469 
(D.N.J. Oct. 5, 2006)      0 0 
Ortho-McNeil-Janssen Pharm. Inc. v. Watson 
Labs. Inc., No. 08-5103(SRC), 2011 WL 
254313 (D.N.J. Oct. 5, 2006)           0 0 
Ranbaxy Labs. Ltd v. Abbott Labs., No. 04-
CV-8078, 2005 WL 3050608 (N.D. Ill. Nov. 10, 
2005)           0 0 
Schering Corp. v. Mylan Pharm. Inc., No. 09-
CV-6383, 2011 WL 3736503 (D.N.J. Aug. 22, 
2011)      0 0 
Senju Pharm. Co. Ltd v. Apotex Inc., 717 F. 
Supp. 2d 404 (D. Del. 2010)           0 0 
SmithKline Beecham Corp. v. Apotex Corp., 
286 F. Supp. 2d 925 (N.D. Ill. 2001)           0 0 
SmithKline Beecham Corp. v. Apotex Corp., 
403 F.3d 1331 (Fed. Cir. 2005)      0 0 
Takeda Pharm. Co, Ltd v. Handa Pharm., 
LLC, No. 11-CV-840, 2012 WL 1243109 (N.D. 
Cal. Apr. 11, 2012)           0 0 
Wyeth v. Mylan Pharm. Inc., No. 07-CV-91, 
2009 WL 3335062 (N.D. W. Va. Oct. 14, 2009)      0 0 
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Legend:  1 = Written Description Valid as a Matter of Law; 2 = Written Description Fact Issue—
Valid; 3 = Written Description Invalid as a Matter of Law; 4 = Written Description Fact Issue—
Invalid; 5 = Written Description Fact Issue—Remaining  
 
Non-ANDA Opinions 1 2 3 4  5 
Written Description 
3-level 5-level 
Allergan Inc. v. Watson Labs. Inc., 869 F. 
Supp. 2d 456 (D. Del. 2012)   1       3 4 
Emory Univ. v. Glaxo Wellcome Inc., 96-CV-
1868, 1997 WL 817342 (N.D. Ga. July 14, 
1997)         1 2 3 
O’Hara Mfg. Ltd v. Eli Lilly & Co., No. 85-cv-
3979, 1986 WL 8391 (N.D. Ill. July 21, 1986)         1 2 3 
Oakwood Labs. v. Tap Pharm. Prods. Inc., 
No. 01-CV-7631, 2003 WL 22400759 (N.D. Ill. 
2003)         1 2 3 
AbbVie Deutschland GmbH & Co., KG v. 
Janssen Biotech, Inc., 759 F.3d 1285 (Fed. Cir. 
2014)       1   1 2 
Eli Lilly & Co. v. Teva Pharm. USA Inc., 619 
F.3d 1329 (Fed. Cir. 2010)       1   1 2 
Purdue Pharma LP v. Faulding Inc., 230 F.3d 
1320 (Fed. Cir. 2000)       1   1 2 
Centocor Ortho Biotech Inc. v. Abbott Labs., 
636 F.3d 1341 (Fed. Cir. 2011)     1     1 1 
Univ. of Rochester v. G.D. Searle & Co., 358 
F.3d 916 (Fed. Cir. 2004)     1     1 1 
Abbott GMBH & Co., KG v. Centocor Ortho 
Biotech, Inc., 870 F. Supp. 2d 206 (D. Mass. 
2012)           0 0 
Abbott Labs. v. Teva Pharm. USA Inc., No. 
02-CV-1512, 2005 WL 6225546 (D. Del. May 
6, 2005)           0 0 
ALZA Corp. v. Andrx Pharm., LLC, 603 F.3d 
935 (Fed. Cir. 2010)           0 0 
Amgen Inc v. Chugai Pharm. Co. Ltd., 927 
F.2d 1200 (Fed. Cir. 1991)           0 0 
Amgen Inc. v. F. Hoffman-LA Roche Ltd., 
580 F.3d 1340 (Fed. Cir.2009)           0 0 
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Legend:  1 = Written Description Valid as a Matter of Law; 2 = Written Description Fact Issue—
Valid; 3 = Written Description Invalid as a Matter of Law; 4 = Written Description Fact Issue—
Invalid; 5 = Written Description Fact Issue—Remaining  
 
Non-ANDA Opinions 1 2 3 4  5 
Written Description 
3-level 5-level 
Apotex, Inc. v. UCB, Inc., 970 F. Supp. 2d 
1297 (S.D. Fla. 2013)           0 0 
Aventis Pharma S.A. v. Hospira Inc., 743 F. 
Supp. 2d 305 (D. Del. 2010)           0 0 
Glaxo Group Ltd v. Kali Labs. Inc., 03-CV-
399, 2005 WL 1793728 (D.N.J. July 27, 2005)           0 0 
Graceway Pharm. LLC v. Perrigo, No. 10-CV-
937, 2011 WL 3206481 (D.N.J. July 27, 2011)           0 0 
Hoffman-La Roche Inc. v. Lemmon Co., No. 
84-CV-4303, 1989 WL 89241 (E.D. Pa. Aug. 7, 
1989).           0 0 
Liposome Co. Inc. v. Vestar Inc., No. 92-CV-
332, 1994 WL 738952 (D. Del. Dec. 20, 1994)           0 0 
McNeil-PPC Inc. v. Perrigo Co., No. 05-CV-
1321, 2007 WL 81918 (S.D.N.Y. Jan. 12, 2007)           0 0 
Medicis Pharm. Corp. v. Acella Pharm. Inc., 
No. 10-CV-1780, 2011 WL 810044 (D. Ariz. 
Mar. 2, 2011)           0 0 
N. Am. Vaccine Inc. v. Am. Cyanamid Co., 7 
F.3d 1571 (Fed. Cir. 1993)           0 0 
Pharm. Res. Inc. v. Roxane Labs. Inc., 253 
Fed. App’x 26 (Fed. Cir. 2007)           0 0 
Teva Pharm. USA, Inc. v. Sandoz, Inc., 723 
F.3d 1363 (Fed. Cir. 2013)           0 0 
Tristrata Tech. Inc. v. ICN Pharm. Inc., 313 F. 
Supp. 2d 405 (D. Del. 2004)           0 0 
UCB Inc. v. KV Pharm. Co., 08-CV-223, 2009 
WL 2524519 (D. Del. Aug. 18, 2009)           0 0 
Unigene Labs. Inc. v. Apotex Inc., No. 06-
CV-5571, 2010 WL 2730471 (S.D.N.Y. July 7, 
2010)           0 0 
Warner Lambert Co. v. Teva Pharm. USA 
Inc., No. 99-CV-922, 2007 WL 4233015 
(D.N.J. Nov. 29, 2007)           0 0 
